Should You Buy This Cannabis Stock While It's Under $2?

Canopy Growth (NASDAQ: CGC) remains under pressure with shares trading below $2 as the company struggles with systemic weaknesses in the Canadian cannabis market—slow revenue growth, persistent net losses, and intense competition. A late-2025 U.S. executive order reclassifying cannabis to Schedule 3 should ease banking access and tax deductibility and support sector-wide fundamentals, but it is unlikely to materially alter Canopy’s outlook given federal-state restrictions, cross‑border limitations, and fierce competition both in Canada and the U.S. Investors should treat the firm as high risk given weak company fundamentals and uncertain prospects despite favorable regulatory developments.

Analysis

Market structure: Federal rescheduling to Schedule III is a positive structural shift for U.S. MSOs and banks (lower compliance costs, access to fiat banking, potential 280E relief), but interstate commerce and full national scale require congressional action — so expect fragmented regional winners (CURLF, CRLBF) and continued price competition in Canada (CGC remains disadvantaged). Banking/insurance/ancillary service providers will capture most early economic benefits; commodity input demand rises modestly but not enough to reorder supply chains.

Risk assessment: Immediate (days) — headline-driven volatility and squeezes in low-liquidity names (CGC) with +/-20–40% moves; short-term (weeks–months) — banks and MSOs trading on guidance from FDIC/IRS; long-term (12–36 months) — true profit expansion only if 280E tax relief is codified and interstate commerce is legalized. Tail risks include reversal via litigation/executive action, delayed IRS guidance, or a credit event at a large MSO; hidden dependency: banks’ risk appetite, not law change, governs practical benefit.

Trade implications: Alpha accrues to U.S. MSOs and ancillaries; Canadian multi-licence growers with domestic retail exposure (CGC) face persistent margin pressure. Expect credit spreads for weaker Canadian issuers to widen and implied equity vol for CGC to remain elevated; short-dated options can monetize this.

Contrarian angles: Consensus prices in permanent Canadian underperformance; if Congress acts within 12–24 months to legalize interstate commerce, CGC could re-rate through M&A or scale — but probability is low (<30%). The market may be over-discounting U.S. upside early; focus on balance-sheet strength, access to capital, and near-term cash flow conversion rather than headline rescheduling alone.

Key Decisions for Investors

• Establish a 2–3% short position in Canopy Growth (CGC) equity or buy 3–6 month put options (strike $1.50–$2.00) targeting a 40–60% downside within 6–12 months if no substantive IRS/FDIC guidance; use a hard stop at 30% adverse move.
• Establish a 2–3% long position in a large U.S. MSO (e.g., Curaleaf CURLF or Cresco CRLBF) funded by the CGC short; complement with a 3–9 month call vertical (buy ATM, sell +20–30% OTM) to limit cost and capture regional roll-up/M&A upside.
• Reduce exposure to Canada-focused cannabis ETFs/equities (e.g., HMMJ) by at least 50% of current weight and redeploy 1–2% into cannabis-adjacent ancillaries (e.g., Scotts Miracle-Gro SMG) and select regional banks likely to onboard cannabis clients (expect 6–12 month benefit).
• Sell implied volatility on CGC via covered calls or put spreads if liquidity permits — target IV > 80% and collect premium over 3–6 months; avoid naked short exposure. Monitor three catalysts over next 30–90 days: IRS 280E guidance, FDIC/FinCEN bank letters, and any congressional bills on interstate commerce — adjust positions if 280E rollback probability rises above 50%.